Keming Gao1, Stephen J Ganocy2, Carla Conroy2, Brittany Brownrigg2, Mary Beth Serrano2, Joseph R Calabrese2. 1. Mood and Anxiety Clinic in the Mood Disorders Program, University Hospital Cleveland Medical Center, Case Western Reserve University School of Medicine, 10524 Euclid Avenue, 12th Floor, Cleveland, OH, 44106, USA. Keming.gao@uhhospitals.org. 2. Mood and Anxiety Clinic in the Mood Disorders Program, University Hospital Cleveland Medical Center, Case Western Reserve University School of Medicine, 10524 Euclid Avenue, 12th Floor, Cleveland, OH, 44106, USA.
Abstract
OBJECTIVE: This study aims to compare treatment response in bipolarI or II depression and generalized anxiety disorder (GAD) with and without recent alcohol and/or cannabis use disorder (ALC/CAN) to quetiapine-XR (extended release) or placebo. METHODS: A randomized, double-blind, 8-week study of quetiapine-XR versus placebo in patients with bipolar I or II depression and GAD with or without a recent ALC/CAN was used to compare changes in Hamilton Depression Rating Scale-17, Hamilton Anxiety Rating Scale, the 16-item Quick Inventory of Depressive Symptomatology-Self-Report (QIDS-SR-16), Clinical Global Impression for Bipolar Disorder-Severity (CGI-BP-S), and Timeline Follow Back within and between groups. RESULTS: In the quetiapine-XR group, patients with a recent ALC/CAN (n = 22) had significant decreases in QIDS-SR-16 (-9.6 ± 1.6 vs. -3.7 ± 1.7) and CGI-BP-S (-1.6 ± 0.4 vs. -0.8 ± 0.03) than those without a recent ALC/CAN (n = 24). In the placebo group, both patients with a recent ALC/CAN (n = 23) and those without (n = 21) had similar reductions in these measures. The reduction of QIDS-SR-16 scores in patients with a recent ALC/CAN was also significantly different from that of their counterparts in the placebo group. Patients who received quetiapine-XR had larger decreases in the number of drinking days/week (p = 0.17) and number of cannabis joints/week (p = 0.09) compared to those who received placebo. CONCLUSION:Quetiapine-XR was superior to placebo in reducing QIDS-SR-16 total score in patients with a recent ALC/CAN. Patients taking quetiapine-XR used less alcohol and cannabis than patients on placebo, suggesting that quetiapine-XR may be of use in patients with bipolar disorder accompanied by GAD and other comorbidities.
RCT Entities:
OBJECTIVE: This study aims to compare treatment response in bipolar I or II depression and generalized anxiety disorder (GAD) with and without recent alcohol and/or cannabis use disorder (ALC/CAN) to quetiapine-XR (extended release) or placebo. METHODS: A randomized, double-blind, 8-week study of quetiapine-XR versus placebo in patients with bipolar I or II depression and GAD with or without a recent ALC/CAN was used to compare changes in Hamilton Depression Rating Scale-17, Hamilton Anxiety Rating Scale, the 16-item Quick Inventory of Depressive Symptomatology-Self-Report (QIDS-SR-16), Clinical Global Impression for Bipolar Disorder-Severity (CGI-BP-S), and Timeline Follow Back within and between groups. RESULTS: In the quetiapine-XR group, patients with a recent ALC/CAN (n = 22) had significant decreases in QIDS-SR-16 (-9.6 ± 1.6 vs. -3.7 ± 1.7) and CGI-BP-S (-1.6 ± 0.4 vs. -0.8 ± 0.03) than those without a recent ALC/CAN (n = 24). In the placebo group, both patients with a recent ALC/CAN (n = 23) and those without (n = 21) had similar reductions in these measures. The reduction of QIDS-SR-16 scores in patients with a recent ALC/CAN was also significantly different from that of their counterparts in the placebo group. Patients who received quetiapine-XR had larger decreases in the number of drinking days/week (p = 0.17) and number of cannabis joints/week (p = 0.09) compared to those who received placebo. CONCLUSION:Quetiapine-XR was superior to placebo in reducing QIDS-SR-16 total score in patients with a recent ALC/CAN. Patients taking quetiapine-XR used less alcohol and cannabis than patients on placebo, suggesting that quetiapine-XR may be of use in patients with bipolar disorder accompanied by GAD and other comorbidities.
Authors: E Sherwood Brown; Prabha Sunderajan; Lisa T Hu; Sharon M Sowell; Thomas J Carmody Journal: Neuropsychopharmacology Date: 2012-06-06 Impact factor: 7.853
Authors: Roger D Weiss; Margaret L Griffin; Monika E Kolodziej; Shelly F Greenfield; Lisa M Najavits; Dennis C Daley; Heidi Ray Doreau; John A Hennen Journal: Am J Psychiatry Date: 2007-01 Impact factor: 18.112
Authors: E Sherwood Brown; Jackie Peterson Todd; Lisa T Hu; Joy M Schmitz; Thomas J Carmody; Alyson Nakamura; Prabha Sunderajan; A John Rush; Bryon Adinoff; Mary Ellen Bret; Traci Holmes; Alexander Lo Journal: Am J Psychiatry Date: 2015-05-22 Impact factor: 18.112
Authors: Keming Gao; Zuowei Wang; Jun Chen; David E Kemp; Philip K Chan; Carla M Conroy; Mary Beth Serrano; Stephen J Ganocy; Joseph R Calabrese Journal: J Affect Disord Date: 2012-12-28 Impact factor: 4.839
Authors: Keming Gao; Renrong Wu; Zuowei Wang; Ming Ren; David E Kemp; Philip K Chan; Carla M Conroy; Mary Beth Serrano; Stephen J Ganocy; Joseph R Calabrese Journal: J Psychiatr Res Date: 2014-09-19 Impact factor: 4.791
Authors: Keming Gao; Bryan K Tolliver; David E Kemp; Marcia L Verduin; Stephen J Ganocy; Sarah Bilali; Kathleen T Brady; Seong S Shim; Robert L Findling; Joseph R Calabrese Journal: J Affect Disord Date: 2008-01-29 Impact factor: 4.839